Janssen seeks FDA OK for darunavir/cobicistat HIV fixed-dose combo
This article was originally published in Scrip
Executive Summary
Johnson & Johnson subsidiary Janssen is seeking the FDA's blessing to market a once-daily fixed-dose combination (FDC) tablet for HIV containing darunavir, a protease inhibitor currently marketed under the brand name Prezista, with cobicistat, an investigational boosting agent, which was developed by Gilead Sciences.